$CI

Cigna Healthcare, part of The Cigna Group (CI), launched Health Sense, a support model to reduce inefficient healthcare spending by 10% by 2030. The system connects health, care, and cost data to personalize support. Initial rollout in 2027 will focus on oncology and cardiometabolic health needs, with plans to expand. The company cited existing program results showing higher provider engagement and annual savings of $5,851 for oncology care management.

Piper Sandler kept an Overweight rating on Cigna Group with a $370 price target, suggesting a 38.1% upside from the Oct 1 close. The firm highlights Cigna's long-term EPS growth outlook of 10-14% and a $3B efficiency initiative.

Bernstein raised its price target for Cigna (NYSE:CI) to $387, citing growth in specialty pharmacy. Cigna set 2026-2030 targets, including 10-14% adjusted earnings growth. Q2 2026 earnings beat expectations, with $7.78 EPS and $71.7B revenue. Analysts have mixed outlooks, with UBS targeting $400 and Evercore ISI at $290.

UBS reiterated a Buy rating and $400 price target for Cigna (CI), citing its 2026-2030 outlook. Cigna expects $280B revenue and $30.45 EPS by 2026, with 10-14% EPS growth through 2030. The company also reported Q2 earnings and revenue above estimates. Guggenheim raised its target to $361, while Evercore ISI initiated coverage with a $290 target.

Cigna (CI) reaffirmed 2026 targets, including $280B revenue and $30.45 EPS. The company will exit the ACA marketplace, cut insurance growth targets, and focus on specialty pharmacy. Shares fell 2% intraday. CI also launched an AI program to reduce medical costs by $200M over three years.

Cigna Group (NYSE:CI) presented its 'Lead to One' strategic growth framework at Investor Day, targeting $280B in revenues and $30.45 EPS by 2026. The company aims for 10-14% adjusted EPS growth and $50B in cash flow by 2030, launching a $3B modernization initiative. Shares were down 0.44% at $274.04.

Cigna (CI) announced a $3B multi-year initiative to enhance performance using AI and productivity tools. The company also outlined financial targets for 2026–2030 during its Investor Day.

Cigna Group (CI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities • Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned

The Cigna Group (CI) hosted its 2026 Investor Day, introducing the 'Lead to One' vision to drive growth through personalization and complex care leadership. The company reaffirmed its 2026 financial guidance, including $280B in revenues and $30.45 in adjusted EPS, and set long-term targets of 10-14% adjusted EPS CAGR through 2030. A $3B multi-year modernization initiative was also announced.

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.